Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: Comparison with p53 alterationslymph node invasion

International Journal of Oncology

Volumn 11, Issue 3, 1997, Pages 617-621

  Collet, Brigitte ^a   Raoul, Jean Luc ^a   Le Berre, Nathalie ^b   Heresbach, Denis ^b   Meritte, Hélène ^a   Quillien, Véronique ^a   De Certaines, Jacques Donald ^a  

^a Ctr Reg de Lutte Contre le Cancer   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Esophagus; Immunoassay; P53 antibodies; P53 gene; Squamous cell carcinoma

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SERUM; SQUAMOUS CELL CARCINOMA;

EID: 0030789994     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455, 1996.
2. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
3. Greenblatt MS, Benett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
4. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48, 1994.
5. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwanz L, Chen L-C, Mayall BH and Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855, 1992.
6. Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
7. Angelopoulou K, Diamandis EF, Sutherland DJA, Kellen JA and Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487, 1994.
8. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild C and Soussi T: P53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res 1: 1463-1469, 1995.
9. Peyrat JP, Bonneterre J, Lubin J, Vanlemmens L, Fournier J and Soussi T: Prognostic significance of circulating p53 in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621-622, 1995.
10. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F and Soussi T: Analysis of p53 serum antibodies in a series of patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 1228-1233, 1996.
11. Trivers GE, De Benedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD and Harris CC: Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2: 1767-1775, 1996.
12. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A and Soussi T: Serum p53 antibodies as early markers of lung cancer. Nature Med 1: 701-702, 1995.
13. Trivers GE, Cawley HL, DeBenedetti VMG, Hollstein M, Marion MJ, Benett WP, Hoover ML, Prives CC, Tamburro CC and Harris CC: Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87: 1400-1407, 1995.
14. Audrezet MP, Robaszkiewicz M, Mercier B, Nousbaum JB, Bail JP, Hardy E, Volant A, Lozac'h P, Charles JF, Gouerou H and Ferec C: TP 53 gene mutation profile in esophageal squamous cell carcinomas. Cancer Res 53:5745-5749, 1993.
15. Wang LD, Hong JY, Qiu SL, Gao H and Yang CS: Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res 53: 1783-1787, 1993.
16. Hamelin R, Jego N, Laurent-Puig P, Vidaud M and Thomas G: Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 8: 2213-2220, 1993.
17. Von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VMG, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N and Trivers GE: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56:4917-4921, 1996.
18. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Trédaniel J, Hirsch A, Caron de Fromentel C, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig L, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B and Soussi T: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872-5876, 1993.
19. Wild CP, Ridanpää M, Anttila S, Lubin R and Soussi T: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 64: 176-181, 1995.
20. Davidoff AM, Iglehart JD and Marks JR: Imniune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442, 1992.
21. Volkmann M, Müller M, Hofmann WJ, Meyer M, Hagelstein J, Räth U, Kommerell B, Zentgraft H and Galle P: The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 18: 559-565, 1993.
22. Preudhomme C, Lubin R, Lepelley P, Vanrumbeke M and Fenaux P: Detection of serum antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8: 1589-1591, 1994.
23. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
24. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
25. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Brand A, van de Velde CJH and Melief CJM: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 637-641, 1995.